Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF<sup>V600E</sup>-Mutant CRC: A Case Report and Review.

Cho, Su Min; Esmail, Abdullah; Abdelrahim, Maen

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF^V600E-Mutant CRC: A Case Report and Review.

Cho, Su Min; Esmail, Abdullah; Abdelrahim, Maen.

Afiliação

Cho SM; Department of Medicine, Houston Methodist Hospital, Houston, TX, United States.
Esmail A; Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX, United States.
Abdelrahim M; Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX, United States.

Front Pharmacol ; 12: 795381, 2021.

Article em En | MEDLINE | ID: mdl-34975492

Palavras-chave

BRAF, CRC; Chemotherapy; Immunotherapy; Irinotecan, Cetuximab; Metastasis; SWOG; Vemurafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article